Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D Michelson

Showing results (291-300 of 339) with videos related to

Pageof 34
Sort By:
Thrombosis and Haemostasis|June 29, 2007
The active metabolite of prasugrel inhibits ADP-stimulated thrombo-inflammatory markers of platelet activation: Influence of other blood cells, calcium, and aspirinAndrew L Frelinger, Joseph A Jakubowski, Youfu Li, et al.
Anesthesia and Analgesia|December 20, 2008
A novel process for introducing a new intraoperative program: a multidisciplinary paradigm for mitigating hazards and improving patient safetyJose M Rodriguez-Paz, Lynette J Mark, Kurt R Herzer, et al.
Journal of Obstetric, Gynecologic, and Neonatal Nursing : JOGNN|August 22, 2020
Women's Experiences of the Effect of Financial Strain on Parenting and Mental HealthLucy E Marcil, Jeffrey I Campbell, Katie E Silva, et al.
Thrombosis and Haemostasis|March 25, 2016
Diabetes mellitus, CYP2C19 genotype, and response to escalating doses of clopidogrel. Insights from the ELEVATE-TIMI 56 TrialEdward T Carreras, Willibald Hochholzer, Andrew L Frelinger, et al.
Journal of Vascular Surgery|February 4, 2003
The cleaved peptide of PAR1 is a more potent stimulant of platelet-endothelial cell adhesion than is thrombinR Brannon Claytor, Alan D Michelson, Jian-Ming Li, et al.
American Heart Journal|May 28, 2019
Rivaroxaban, a direct Factor Xa inhibitor, versus acetylsalicylic acid as thromboprophylaxis in children post-Fontan procedure: Rationale and design of a prospective, randomized trial (the UNIVERSE study)Liza Miriam Pina, Xiangwen Dong, Liping Zhang, et al.
Acta Haematologica|June 12, 2013
Clinical and laboratory significance of defective P2Y(12) pathway function in patients with myeloproliferative neoplasms: a pilot studyHung Chang, Lee-Yung Shih, Alan D Michelson, et al.
Journal of the American College of Cardiology|January 22, 2013
Clopidogrel pharmacokinetics and pharmacodynamics vary widely despite exclusion or control of polymorphisms (CYP2C19, ABCB1, PON1), noncompliance, diet, smoking, co-medications (including proton pump inhibitors), and pre-existent variability in platelet functionAndrew L Frelinger, Deepak L Bhatt, Ronald D Lee, et al.
Journal of the American College of Cardiology|October 5, 2001
Circulating monocyte-platelet aggregates are an early marker of acute myocardial infarctionM I Furman, M R Barnard, L A Krueger, et al.
European Heart Journal|January 22, 2011
A pharmacodynamic comparison of prasugrel vs. high-dose clopidogrel in patients with type 2 diabetes mellitus and coronary artery disease: results of the Optimizing anti-Platelet Therapy In diabetes MellitUS (OPTIMUS)-3 TrialDominick J Angiolillo, Juan Jose Badimon, Jorge F Saucedo, et al.
Pageof 34

Showing results (291-300 of 339) with videos related to

Sort By:
Pageof 34
Thrombosis and Haemostasis|June 29, 2007
The active metabolite of prasugrel inhibits ADP-stimulated thrombo-inflammatory markers of platelet activation: Influence of other blood cells, calcium, and aspirinAndrew L Frelinger, Joseph A Jakubowski, Youfu Li, et al.
Anesthesia and Analgesia|December 20, 2008
A novel process for introducing a new intraoperative program: a multidisciplinary paradigm for mitigating hazards and improving patient safetyJose M Rodriguez-Paz, Lynette J Mark, Kurt R Herzer, et al.
Journal of Obstetric, Gynecologic, and Neonatal Nursing : JOGNN|August 22, 2020
Women's Experiences of the Effect of Financial Strain on Parenting and Mental HealthLucy E Marcil, Jeffrey I Campbell, Katie E Silva, et al.
Thrombosis and Haemostasis|March 25, 2016
Diabetes mellitus, CYP2C19 genotype, and response to escalating doses of clopidogrel. Insights from the ELEVATE-TIMI 56 TrialEdward T Carreras, Willibald Hochholzer, Andrew L Frelinger, et al.
Journal of Vascular Surgery|February 4, 2003
The cleaved peptide of PAR1 is a more potent stimulant of platelet-endothelial cell adhesion than is thrombinR Brannon Claytor, Alan D Michelson, Jian-Ming Li, et al.
American Heart Journal|May 28, 2019
Rivaroxaban, a direct Factor Xa inhibitor, versus acetylsalicylic acid as thromboprophylaxis in children post-Fontan procedure: Rationale and design of a prospective, randomized trial (the UNIVERSE study)Liza Miriam Pina, Xiangwen Dong, Liping Zhang, et al.
Acta Haematologica|June 12, 2013
Clinical and laboratory significance of defective P2Y(12) pathway function in patients with myeloproliferative neoplasms: a pilot studyHung Chang, Lee-Yung Shih, Alan D Michelson, et al.
Journal of the American College of Cardiology|January 22, 2013
Clopidogrel pharmacokinetics and pharmacodynamics vary widely despite exclusion or control of polymorphisms (CYP2C19, ABCB1, PON1), noncompliance, diet, smoking, co-medications (including proton pump inhibitors), and pre-existent variability in platelet functionAndrew L Frelinger, Deepak L Bhatt, Ronald D Lee, et al.
Journal of the American College of Cardiology|October 5, 2001
Circulating monocyte-platelet aggregates are an early marker of acute myocardial infarctionM I Furman, M R Barnard, L A Krueger, et al.
European Heart Journal|January 22, 2011
A pharmacodynamic comparison of prasugrel vs. high-dose clopidogrel in patients with type 2 diabetes mellitus and coronary artery disease: results of the Optimizing anti-Platelet Therapy In diabetes MellitUS (OPTIMUS)-3 TrialDominick J Angiolillo, Juan Jose Badimon, Jorge F Saucedo, et al.
Pageof 34